Beta-CORRECT study shows a 10.6-fold higher risk of recurrence, reinforcing the prognostic value of molecular residual disease (MRD) testing1 Building on its leadership in colorectal ...

Cologuard Plus is a noninvasive, stool-based DNA screening test designed to detect both colorectal cancer and advanced precancerous lesions In the pivotal BLUE-C study, Cologuard Plus ...

The table above provides additional details regarding the specified items described on table titled "Non-GAAP Reconciliation of Financial Information." Restructuring and cost reduction initiative ...

Announcement follows receipt of all regulatory clearances necessary for closing Transaction enables Abbott to enter and lead in fast-growing cancer screening and diagnostics segments, serving millions ...

Note: Operational growth reflects percentage change over the prior year excluding the impact of exchange rates. * Total Abbott Sales from continuing operations include Other Sales of $11 million. n/a ...

The table above provides additional details regarding the specified items described on tables titled "Non-GAAP Reconciliation of Financial Information". a) Acquisition-related expenses include ...

The table above provides additional details regarding the specified items described on table titled "Non-GAAP Reconciliation of Financial Information." Reflects the net tax benefit associated with the ...

ABBOTT PARK, Ill., March 6, 2023 /PRNewswire/ -- Abbott (NYSE: ABT) today announced that the U.S. Food and Drug Administration (FDA) has cleared its FreeStyle Libre 2 and FreeStyle Libre 3 integrated ...

2020 Tax expense on Earnings from Continuing Operations includes the recognition of approximately $135 million of tax benefits related to the impairment of certain assets, approximately $25 million of ...

The table above provides additional details regarding the specified items described on tables titled "Non-GAAP Reconciliation of Financial Information." Restructuring and cost reduction initiative ...

Multi-year collaboration combines ongoing glucose insights from Abbott's Lingo biowearable with Google Health's technology to create a more comprehensive view of personal health Partnership includes a ...